Saturday 17 October 2026
Export MOLN’s income statement to Excel — free account
Molecular Partners AG Sponsored ADR
MOLN Healthcare Biotechnology
In the quarter to June 2026, revenue fell 98.9%, EPS grew 34.3% and free cash flow grew 23.8%, each against the same quarter a year earlier.
3.56
0.09
−2.47%
Follow MOLN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(50.75%) | (57.72%) | (63.08%) | (63.89%) | |
| (44.60%) | (49.07%) | (53.96%) | (52.73%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(56.58%) | (67.69%) | (72.08%) | (77.93%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.75) | (1.68) | (1.63) | (1.48) | |
Free Cash Flow |
(65.06) | (62.73) | (61.04) | (57.35) | |
Capital Expenditures |
(0.86) | (0.86) | — | (0.39) | |
| Other line items | |||||
Cash ROIC |
(26.03%) | (29.97%) | (32.49%) | (35.84%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
18.02 | 22.86 | 18.47 | 20.11 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
19.88 | 16.05 | 18.95 | 17.53 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(25.46) | (11.52) | (14.31) | (106.34) | |
Operating CF/Net income |
0.90 | 0.83 | 0.84 | 0.88 | |
Depreciation/Fixed assets |
0.67 | 0.41 | 0.43 | 0.46 | |
Capex/Depreciation |
(0.32) | (0.33) | 0.00 | (0.16) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.72) | (1.66) | (1.63) | (1.47) | |
Capex per Share |
(0.02) | (0.02) | 0.00 | (0.01) | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 |
Columns are period end dates